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ABSTRACT
Background. Uromodulin is a kidney-specific glycoprotein synthesized in tubular cells of Henle’s loop exerting
nephroprotective and immunomodulatory functions in the urinary tract. A small amount of uromodulin is also released
into the systemic circulation, where its physiological role is unknown. Serum uromodulin (sUmod) has been associated
with metabolic risk factors and with cardiovascular events and mortality, where these associations were partly stronger in
men than in women. In this study, we investigated the associations of sUmod with biomarkers of subclinical inflammation
in a population-based sample of women and men.
Methods. Associations of sUmod with 10 biomarkers of subclinical inflammation were assessed in 1065 participants of the
Cooperative Health Research in the Region of Augsburg (KORA) F4 study aged 62–81 years using linear regression models
adjusted for sex, age, body mass index, estimated glomerular filtration rate and diabetes. Analyses were performed in the
total study sample and stratified by sex.
Results. sUmod was inversely associated with white blood cell count, high-sensitive C-reactive protein, interleukin (IL)-6,
tumour necrosis factor-a, myeloperoxidase, superoxide dismutase-3, IL-1 receptor antagonist and IL-22 after multivariable
adjustment and correction for multiple testing (P<0.001 for each observation). There was a trend towards a stronger
association of sUmod with pro-inflammatory markers in men than in women, with a significant P for sex interaction
(<0.001) regarding the relation of sUmod with IL-6.
Conclusions. sUmod was inversely associated with biomarkers of subclinical inflammation in older participants of the KORA
F4 study. The association of sUmod with IL-6 differed between women and men. Future research should focus on whether
the immunomodulatory properties of sUmod are one explanation for the association of sUmod with cardiovascular
outcomes and mortality.
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INTRODUCTION
Uromodulin (Tamm–Horsfall protein) is a tissue-specific glyco-
protein synthesized in tubular cells of the thick ascending limb
of Henle’s loop. Uromodulin is mostly secreted into the urinary
tract, where it exerts anti-lithogenic, anti-infective and immu-
nomodulatory functions [1–5], but a small amount is also se-
creted into the blood stream (serum uromodulin, sUmod) [6, 7].
The physiological function of sUmod is elusive to date, but
epidemiological evidence indicates that sUmod levels are in-
versely associated with all-cause and cardiovascular mortality
[8–11] as well as with cardio-metabolic risk factors, including di-
abetes [12, 13] and the metabolic syndrome [14]. Remarkably,
these associations are largely independent of the estimated glo-
merular filtration rate (eGFR), indicating that sUmod itself may
play a role in metabolic and cardiovascular health.
Immunomodulatory properties might link sUmod to meta-
bolic and cardiovascular outcomes. Analogous to its role in the
urinary tract, immune-regulative functions of sUmod in the sys-
temic circulation are conceivable. Preclinical studies investigat-
ing this issue yielded inconsistent results. Increased neutrophil
numbers in the kidney and the circulation were reported in
uromodulin-deficient mice, which also displayed an increased
bone marrow granulopoiesis [15]. Patras et al. [16] showed that
uromodulin binds isolated human neutrophils in vitro and that
this interaction reduced the generation of reactive oxygen spe-
cies. Furthermore, uromodulin was shown to bind immunoglob-
ulin G [17], tumour necrosis factor (TNF)-a [18] and complement
1q [19], and inhibited the activation of the classical complement
pathway in vitro [20].
In contrast, other studies indicated a pro-inflammatory role
of uromodulin. Isolated uromodulin was shown to bind and ac-
tivate human granulocytes in vitro, enhancing their interleukin
(IL)-8 expression [4]. Further studies showed that uromodulin
activated myeloid dendritic cells via toll-like receptor-4 to
acquire a fully mature dendritic cell phenotype [21] and isolated
human monocytes to secrete pro-inflammatory cytokines in-
cluding IL-1b [5].
Data on the association of sUmod with markers of subclini-
cal inflammation in a large epidemiological study are lacking.
Therefore, we investigated the association of sUmod with
markers that may increase in response to inflammatory stimuli,
including white blood cell count, six pro-inflammatory bio-
markers [high-sensitive C-reactive protein [hsCRP], IL-6, TNF-a,
IL-18, soluble intercellular adhesion molecule-1 (sICAM-1) and
myeloperoxidase (MPO)], and three anti-inflammatory markers
[IL-1 receptor antagonist (IL-1RA), IL-22 and superoxide
dismutase-3 (SOD-3)] in the population-based Cooperative
Health Research in the Region of Augsburg (KORA) F4 study.
Since women have significantly higher sUmod levels than men
[12], we stratified the analyses by sex in addition to the analyses
in the total study sample.
MATERIALS AND METHODS
Study participants
The KORA F4 study involved 3080 participants from the general
community in the region of Augsburg, Southern Germany.
KORA F4, which was the first follow-up examination of KORA S4
(1999–2001), was performed in 2006–08. Study design, recruit-
ment and eligibility criteria, standardized sampling methods
and data collection (medical history, medication, anthropomet-
ric and blood pressure measurements) have been described in
detail elsewhere [22, 23]. All study participants gave written in-
formed consent. The study was approved by the Ethics
Committees of the Bavarian Medical Association in adherence
to the declaration of Helsinki.
Criteria for clinically diagnosed diabetes mellitus were a val-
idated medical diagnosis or current self-reported use of







niversitatsbibliothek Augsburg user on 16 July 2021
glucose-lowering agents. All participants without clinically di-
agnosed diabetes underwent a standard 75 g oral glucose toler-
ance test. Newly diagnosed diabetes was defined according to
the 1999 World Health Organization diagnostic criteria based on
both fasting glucose and glucose values 2 h after intake of the
75 g glucose solution (diabetes: 7.0 mmol/L fasting and/or
11.1 mmol/L 2-h glucose). Participants with diabetes other
than Type 2 diabetes (n¼ 3) or unknown glucose tolerance sta-
tus (n¼ 22) were excluded from the current analysis.
sUmod was measured in 1119 participants aged 62–81 years
of the KORA F4 study with available serum samples (from a total
of 1161 participants in this age group). All variables necessary
for the current analyses were available for 1065 participants.
Laboratory measurements
Blood samples were collected after an overnight fast of at least
8 h and were kept at room temperature until centrifugation.
Plasma was separated immediately, serum after 30 min. Plasma
and serum samples were assayed immediately or stored at
80C. sUmod was measured with a commercially available
enzyme-linked immunosorbent assay (ELISA) kit (Euroimmun
AG, Lübeck, Germany) with a lower detection limit of 2 ng/mL,
an intra-assay coefficient of variation of 2.3% and inter-assay
coefficients of variation of 4.4 and 9.5% for sUmod target values
of 24.9 and 142.2 ng/mL, respectively. The measurement proce-
dure was described by Steubl et al. [7]. hsCRP was determined in
plasma with a high-sensitivity latex-enhanced nephelometric
assay on a BN II analyser (Siemens, Erlangen, Germany). Serum
levels of IL-6 and TNF-a were measured with Quantikine HS
ELISA kits, IL-22, IL-1RA and -1 with Quantikine ELISA kits (R&D
Systems, Wiesbaden, Germany) [24–26]. Plasma levels of IL-18
were determined using ELISA kits from MBL (Nagoya, Japan).
Serum MPO concentrations were measured using the Human
MPO Quantikine ELISA (R&D Systems, Wiesbaden, Germany).
Serum SOD-3 concentrations were measured with an ELISA
from Cloud-Clone Corp. (Houston, TX, USA) [27]. Intra-assay
coefficients of variation for hsCRP, IL-1RA, IL-22, -1, IL-6, TNF-a,
IL-18, MPO and SOD-3 were 2.7, 2.8, 5.5, 3.5, 7.2, 6.3, 7.6, 3.2 and
7.1%, respectively. Interassay coefficients were 6.3, 7.0, 9.3, 6.4,
11.8, 14.4, 9.4, 5.6 and 7.1%, respectively. For IL-22, 332 (31%) of
the sera yielded values below the limit of detection (LOD; 3.9 pg/
mL). Values below LOD were assumed to be evenly distributed
between 0 and LOD and were assigned a value of 0.5 LOD.
Blood glucose levels were assessed using the hexokinase
method (GLU Flex; Dade Behring, Marburg, Germany). Serum
creatinine was determined with a modified Jaffe test (Krea Flex;
Dade Behring). eGFR was calculated using the Chronic Kidney
Disease Epidemiology Collaboration equation (2009) based on
serum creatinine [28].
Statistical analyses
Characteristics of the study participants were compared be-
tween women and men using t-tests in case of approximately
normally distributed variables and Mann–Whitney U-tests for
variables with skewed distributions. Binomial proportions were
compared with Chi-square tests. The associations of sUmod (in-
dependent variable) with biomarkers of subclinical inflamma-
tion were assessed with linear regression models. Continuous
variables were transformed to a Gaussian distribution by proba-
bility integral transformation followed by inverse transform
sampling. b coefficients and their respective standard error
from linear regression models are given per standard deviation
of sUmod. The main model was adjusted for the potential con-
founders sex, age, eGFR, body mass index (BMI) and diabetes,
since these factors may influence subclinical inflammation and
have previously been shown to be associated with sUmod [12,
14]. Active smoking, which potentially induces subclinical in-
flammation, was not related to sUmod (b ¼ 0.02 6 0.12, P ¼
0.85) and therefore not included in the models. Analyses were
computed in the total study sample, as well as in women and
men separately. An alpha level of 0.05 (two-sided) was consid-
ered statistically significant. To account for multiple testing (10
parameters in 3 subgroups¼ 30 tests), we also reported the sig-
nificance of the results setting the threshold at a P < 0.00167
(0.05 30). We tested for sex interaction in order to assess differ-
ences between women and men. For the interaction terms, an
alpha level of 0.1 was considered statistically significant
[P< 0.010 after correction for multiple testing accounting for 10




Table 1 displays the characteristics of the study population.
Whereas the eGFR did not differ significantly between women
and men, sUmod was higher in women (P< 0.001). The white
blood cell count and several proinflammatory biomarkers (IL-6,
TNF-a, IL-18 and MPO), as well as the anti-inflammatory
markers IL-22 and SOD-3, were higher in men. sICAM-1 did not
differ between men and women. hsCRP and the anti-
inflammatory IL-1RA were higher in women.
Association of sUmod with biomarkers of inflammation
Supplementary data, Figure S1 shows the plots of the bio-
markers of subclinical inflammation in dependence of sUmod.
The results of the regression models are given in Table 2. In the
crude analysis in the total cohort, sUmod was inversely associ-
ated with all assessed biomarkers of subclinical inflammation.
The association with sICAM-1 lost significance after adjustment
for confounders, and the association with IL-18 was no longer
significant after additional correction for multiple testing. All
other biomarkers remained significantly inversely associated
with sUmod in the total cohort after adjustment for sex, age,
BMI, eGFR and diabetes, and correction for multiple testing
(P< 0.001 for each observation).
Sensitivity analyses
Due to the functional relationship of TNF-a with IL-6 and of IL-6
with hsCRP, we additionally adjusted the association of sUmod
with IL-6 for TNF-a, which only weakly affected the result (b ¼
0.12 6 0.03; P< 0.001), and the association of sUmod with
hsCRP for IL-6, which moderately attenuated the effect (b:
0.10 6 0.03; P< 0.001). Since IL-22 and IL-1RA are functionally
related, we included IL-22 in the fully adjusted regression model
for the association of sUmod with IL-1RA, which had a modest
effect on the regression coefficient (b ¼ 0.11 6 0.03; P< 0.001).
To evaluate the possible influence of white blood cell count on
the association of sUmod with IL-6, IL-22 and MPO, we included
white blood cell count in the respective fully adjusted regres-
sion models. The results were only weakly attenuated and
remained significant (b ¼ 0.12 6 0.04 for the association of
sUmod with IL-6, b ¼ 0.13 6 0.04 for the association of sUmod
with IL-22, b ¼ 0.12 6 0.03 for the association of sUmod with
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MPO, P< 0.001 for all observations), indicating largely indepen-
dent associations of sUmod with the respective markers of sub-
clinical inflammation.
Sex differences of the association of sUmod with
biomarkers of inflammation
In women, sUmod was significantly inversely related to 6 out of
the 10 assessed biomarkers (white blood cell count, hsCRP,
MPO, IL1-RA, IL-22 and SOD-3) after multivariable adjustment.
After additional correction for multiple testing, MPO, IL-1RA, IL-
22 and SOD-3 remained significantly associated with sUmod.
Interestingly, three of these four biomarkers have primarily
anti-inflammatory functions. The interaction term indicated a
stronger association of sUmod with MPO in women than in
men, which, however, lost significance after correction for mul-
tiple testing.
In men, sUmod was inversely associated with 8 out of the 10
biomarkers after multivariable adjustment, and with 5 bio-
markers after additional correction for multiple testing. These
five biomarkers were white blood cell count, hsCRP, IL-6, TNF-a
and IL-22, four of which have primarily pro-inflammatory prop-
erties. The interaction term showed a stronger association of
sUmod with hsCRP and IL-6 in men compared with women, and
Table 1. Characteristics of the study participantsa
Parameter All participants Women Men P-valueb
N 1065 519 546 –
Age, years 70.3 6 5.5 70.2 6 5.4 70.3 6 5.6 0.888c
BMI, kg/m2 28.7 6 4.5 29.1 6 5.0 28.4 6 3.9 0.021c
Type 2 diabetes, % 207 (19) 81 (16) 126 (23) 0.003e
eGFR, mL/min/1.73 m2 77.9 (67.3–87.7) 76.8 (66.0–87.8) 79.5 (68.2–87.4) 0.349d
sUmod, ng/mL 152.3 (110.6–207.7) 169.9 (120.9–223.8) 138.3 (103.3–188.5) <0.001d
White blood cell count/nL 5.7 (4.9–6.8) 5.6 (4.8–6.8) 5.8 (4.9–7.1) 0.003d
hsCRP, mg/L 1.53 (0.79–3.18) 1.67 (0.91–3.44) 1.44 (0.72–2.99) 0.019d
IL-6, pg/mL 1.61 (1.12–2.45) 1.53 (1.08–2.31) 1.67 (1.14–2.60) 0.034d
TNF-a, pg/mL 2.01 (1.47–2.89) 1.90 (1.43–2.75) 2.05 (1.51–2.98) 0.038d
IL-18, pg/mL 318.0 (251.0–416.0) 290.0 (228.0–370.5) 354.5 (275.5–440.0) <0.001d
sICAM-1, ng/mL 229.8 (199.7–262.7) 231.0 (200.1–264.6) 229.4 (198.2–260.8) 0.630d
MPO, ng/mL 146.3 (95.1–211.5) 138.4 (92.3–198.0) 154.6 (96.5–226.3) 0.005d
IL-1RA, pg/mL 307.4 (236.4–409.7) 316.2 (245.6–419.0) 299.4 (230.4–393.4) 0.044d
IL-22, pg/mL 6.56 (1.95–13.20) 4.64 (1.95–9.07) 9.34 (4.69–16.67) <0.001d
SOD-3, ng/mL 126.2 (111.3–142.4) 122.0 (109.6–140.4) 128.5 (113.9–144.9) <0.001d
aData are presented as mean 6 standard deviation, median (first–third quartile) or absolute numbers (%).




Table 2. Associations between sUmod and biomarkers of inflammation in the total cohort and stratified by sex: b coefficients 6 standard error
from linear regression models are given per standard deviation of sUmod
Total study Women Men Total study Women Men P interactiona
n¼ 1065 n¼ 519 n¼ 546 n¼ 1065 n¼ 519 n¼ 546
Without adjustment Adjustment for (sex), age, BMI, eGFR and diabetes
Pro-inflam
matory biomarkers
White blood cell count 0.17 6 0.03*** 0.14 6 0.04*** 0.19 6 0.05*** 0.12 6 0.03*** 0.09 6 0.04* 0.16 6 0.05** 0.53
hsCRP 0.21 6 0.03*** 0.19 6 0.04*** 0.28 6 0.04*** 0.16 6 0.03*** 0.13 6 0.04** 0.20 6 0.05*** 0.07
IL-6 0.27 6 0.03*** 0.17 6 0.04*** 0.37 6 0.04*** 0.15 6 0.03*** 0.06 6 0.04 0.25 6 0.04*** <0.001
TNF-a 0.18 6 0.03*** 0.13 6 0.04** 0.22 6 0.04*** 0.12 6 0.03*** 0.08 6 0.05 0.15 6 0.05** 0.13
IL-18 0.18 6 0.03*** 0.13 6 0.04** 0.16 6 0.04*** 0.08 6 0.03** 0.07 6 0.05 0.10 6 0.04* 0.62
sICAM-1 0.08 6 0.03** 0.06 6 0.04 0.13 6 0.04** 0.03 6 0.03 0.01 6 0.04 0.07 6 0.05 0.25
MPO 0.18 6 0.03*** 0.21 6 0.04*** 0.11 6 0.04* 0.14 6 0.03*** 0.20 6 0.04*** 0.08 6 0.05 0.08
Anti-inflammatory biomarkers
SOD-3 0.21 6 0.03*** 0.21 6 0.04*** 0.18 6 0.04*** 0.13 6 0.03*** 0.15 6 0.04*** 0.12 6 0.05* 0.41
IL-1RA 0.23 6 0.03*** 0.26 6 0.043*** 0.23 6 0.04*** 0.12 6 0.03*** 0.14 6 0.04*** 0.10 6 0.04* 0.60
IL-22 0.22 6 0.03*** 0.20 6 0.04*** 0.16 6 0.04*** 0.13 6 0.03*** 0.14 6 0.04*** 0.14 6 0.04** 0.34




Bold indicates statistical significance in the fully adjusted model after correcting for multiple testing (corresponding to a P<0.00167 for the linear regression models
and to a P<0.010 for the sex interaction term).
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remained significant for the association of sUmod with IL-6 af-
ter correction for multiple testing.
DISCUSSION
In the population-based KORA F4 study, we found an inverse as-
sociation of sUmod with all assessed biomarkers of subclinical
inflammation except for sICAM-1 and IL-18, which lost signifi-
cance after multivariable adjustment and correction for multi-
ple testing. Remarkably, the associations were largely
independent of the eGFR and do therefore not seem to primarily
depend on kidney function and renal filtration of the inflamma-
tion markers. The inverse associations of sUmod with the in-
flammation markers may indicate an immunoregulatory effect
of sUmod. Possible mechanisms reported from preclinical stud-
ies are binding of these serum components [17–20], downregu-
lation of immune cells [15, 16], inhibiting the c-Jun N-terminal
kinase signalling in proximal epithelial cells [29], a pathway
that may also be involved in the release of cytokines, and en-
hancing the clearance of cytokines as a renal ligand for systemic
cytokine clearance [30, 31]. Concerning the primarily anti-
inflammatory biomarkers, also indirect effects may play a role,
since all three investigated anti-inflammatory markers display
reactive elevations in response to pro-inflammatory stimuli and
cardio-metabolic risk factors.
Association of sUmod with pro-inflammatory
biomarkers
hsCRP, IL-6 and TNF-a are general biomarkers of subclinical in-
flammation and are functionally related [32]. TNF-a activates
the transcription factor nuclear factor-jB, thereby inducing IL-6
expression [33], whereas IL-6 stimulates CRP generation in the
liver [34]. Inclusion of TNF-a in the regression model hardly
influenced the association of sUmod with IL-6. However, adjust-
ment for IL-6 weakened the association of sUmod with hsCRP,
which nevertheless remained significant. These data indicate
that the association of sUmod with pro-inflammatory bio-
markers may partly be influenced by each other.
IL-18 is a pro-inflammatory molecule of the IL-1 family and
was moderately inversely associated with sUmod in our cohort,
but the association lost significance after correction for multiple
testing. sICAM-1 represents a marker of vascular inflammation.
Elevated levels of cell adhesion molecules including sICAM-1 in
the circulation result from increased expression and/or shed-
ding of these proteins from the surface of endothelial cells due
to endothelial cell activation [35]. sUmod was not associated
with sICAM-1 after multivariable adjustment, thereby giving no
hint for direct vasoprotective effects of sUmod.
MPO is a member of the superfamily of haem peroxidases
and catalyses the conversion of H2O2 to reactive oxygen species.
MPO is associated with inflammation, oxidative stress, multiple
cardio-metabolic risk factors and incident cardiovascular events
[36–38]. MPO is mainly expressed in neutrophils and monocytes
[39]. In line with the inverse association of sUmod with MPO in
our cohort, Delgado et al. [11] showed a lower percentage of neu-
trophils with increasing sUmod values in their cohort of
patients admitted for coronary angiography. Correspondingly,
we here show an inverse association of sUmod with white blood
cell count although we cannot provide a differential leucocyte
count.
Association of sUmod with anti-inflammatory
biomarkers
Extracellular SOD-3 is a major antioxidant enzyme in the circu-
lation catalysing the dismutation of superoxide radicals (O2 to
H2O2). Gene variants associated with lower SOD-3 levels are re-
lated to a higher cardiovascular risk [40]. However, SOD-3
appears to undergo reactive elevation in cardio-metabolic risk
situations [41] and is produced in response to reactive oxygen
species and pro-inflammatory cytokines. Interestingly, a recent
preclinical study reported increased oxidative stress in
uromodulin-deficient mice [29], a possible mechanism mediat-
ing increased SOD-3 expression.
IL-1RA represents an anti-inflammatory cytokine from the
IL-1 family. IL-1RA inhibits the action of IL-1b, one of the most
potent inducers of innate immunity, by blocking its receptor
[42]. In experimental studies, IL-1RA deficiency fuelled arterial
inflammation and atherosclerosis [43, 44]. On the other hand,
IL-1RA levels may increase secondary to IL-1b-related processes
[42] and were shown to be elevated in individuals with meta-
bolic risk factors, such as obesity, insulin resistance and Type 2
diabetes [45, 46]. Therefore, despite protective properties, higher
circulation IL-1RA levels may indicate a higher risk for Type 2
diabetes [47] and cardiovascular disease [25].
Similarly, IL-22 may be increased secondarily to cardio-
metabolic risk factors. IL-22 is a member of the IL-10 cytokine
family produced by different leucocyte subsets and limits sys-
temic inflammation [48]. Nonetheless, IL-22 was positively as-
sociated with cardiovascular risk parameters (male sex, current
smoking and lower high density lipoprotein) [26] and may thus
represent a biomarker for a systemic response against cardio-
metabolic risk situations. IL-22 is implicated in the production
of IL-1RA [49], suggesting that IL-22 may contribute to higher IL-
1RA levels. Furthermore, the proinflammatory cytokine IL-1b is
not only a positive regulator of IL-1RA, but also of IL-22 [48].
However, inclusion of IL-22 into the model only weakly influ-
enced the association of sUmod with IL-1RA, indicating no
major interference.
Potential sex differences in the association of sUmod
with biomarkers of inflammation
We observed sex differences in the associations of sUmod with
various immune biomarkers. Overall, women showed more and
stronger inverse associations of sUmod with anti-inflammatory
than with pro-inflammatory biomarkers, except for MPO, which
was the only analysed pro-inflammatory biomarker displaying
a stronger association with sUmod in women than in men. In
men, the inverse associations of sUmod were more pronounced
with pro-inflammatory biomarkers. Men displayed a stronger
association of sUmod with hsCRP and IL-6 than women with a
highly significant P-value for interaction regarding IL-6. White
blood cell count, TNF-a and IL-18 also showed a stronger inverse
association with sUmod in men, although the sex interaction
term was not significant for these parameters.
These observations may indicate that sUmod might have a
stronger immunoregulatory effect in men than in women, de-
spite the higher sUmod levels in women. Interestingly, the in-
verse association of sUmod with all-cause and cardiovascular
mortality and with Type 2 diabetes was only present in men in
our cohort [8, 12]. Hypothetically, different sUmod properties in
women and men are conceivable, with hormonal factors play-
ing a role. For example, uromodulin isolated from the urine of
pregnant women has different immunomodulatory properties
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compared with uromodulin from men and non-pregnant
women, probably due to an altered uromodulin glycosylation
state [50]. Whether such differences are also detectable in
sUmod and may also account for postmenopausal women (as
were included in the current study) remains to be clarified.
Study strengths and limitations
Strengths of our study are the population-based design with a
large, well-characterized population-based study sample.
However, only participants aged 62–81 years were included.
Therefore, the associations of sUmod with biomarkers of in-
flammation remain to be confirmed in a younger population.
Due to the observational nature of our study, we are not able to
provide data on causal relationships and mechanistic links and
cannot exclude reverse causation, i.e. inflammatory reactions
decreasing sUmod.
CONCLUSIONS
sUmod was independently inversely associated with multiple
biomarkers of subclinical inflammation in older adults from a
general population. The data strengthen the view that uromo-
dulin in addition to its renal functions also has systemic immu-
nomodulatory effects. The associations partly differed between
women and men with a trend towards stronger inverse associa-
tions of sUmod with anti-inflammatory biomarkers in women
and with pro-inflammatory biomarkers in men. Future studies
will clarify whether immunomodulatory properties of sUmod
are responsible for its inverse association with cardiovascular
events and mortality, and whether the differences in the associ-
ations of sUmod with biomarkers of inflammation between
sexes are one explanation of the divergent associations of
sUmod with all-cause and cardiovascular mortality and with
Type 2 diabetes in women and men.
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Euroimmun, Lübeck for providing the uromodulin assay
and quality control. We gratefully acknowledge the contri-
bution of all field staff members conducting the KORA F4
study and thank all study participants.
FUNDING
The study was supported by a research grant from the
Virtual Diabetes Institute (Helmholtz Zentrum München),
the Clinical Cooperation Group Diabetes, Ludwig-
Maximilians-University München and Helmholtz Zentrum
München and by the German Diabetes Centre. The German
Diabetes Centre was supported by the Federal Ministry of
Health (Berlin, Germany) and the Ministry of Culture and
Science of the state North-Rhine Westphalia (Düsseldorf,
Germany). The KORA study was initiated and financed by
the Helmholtz Zentrum München-German Research Centre
for Environmental Health, which is funded by the German
Federal Ministry of Education and Research (BMBF) and by
the State of Bavaria. This study was also supported by
grants from the German Federal Ministry of Education and
Research (BMBF) to the German Centre for Diabetes
Research e. V. (DZD). Further support was obtained from the
Deutsche Diabetes Gesellschaft (DDG) and the German
Research Foundation (DFG, grant RA-45913/3-1). The fund-
ing sources had no role in the study design; in the collection,
analysis and interpretation of data; in the writing of the re-
port; and in the decision to submit the article for
publication.
AUTHORS’ CONTRIBUTIONS
Conception and design of the study was done by C.T., B.T.,
C.M., C.Herder, C.Huth, M.R., M.H., A.P., W.K., W.R., M.S.,
H.M., T.M., J.Scherberich and J.Seissler; collection of data by
B.T., C.T., C.M., C.Herder, C.Huth, M.R., M.H., A.P., W.K., W.R.,
A.L., M.S., T.M., J.Scherberich and J.Seissler; data analysis,
interpretation of results, writing of the manuscript was by
C.T., H.T., A.L., J.Scherberich and J.Seissler; all authors re-
vised the manuscript critically for intellectual content and
approved the final version.
CONFLICT OF INTEREST STATEMENT
C.Herder reports grants and personal fees from Sanofi and
Lilly. W.K. reports personal fees from AstraZeneca, Novartis,
Pfizer, The Medicines Company, from DalCor, Kowa, Amgen,
Corvidia, Daiichi-Sankyo, Berlin-Chemie, Sanofi and Bristol-
Myers Squibb, and grants and non-financial support from
Singulex, Abbott, Roche Diagnostics and Beckmann. M.R.
reports personal fees from Eli Lilly, Poxel S.A. Société,
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